What was Evonik's adjusted EBITDA for Q2 2026, and how does it compare year-on-year?

Evonik's adjusted EBITDA for Q2 2026 was €630 million, representing a 24% year-on-year increase. This figure aligns with the company's preliminary data released on June 26, 2026, and falls within its earlier guidance range of €600–€650 million for the quarter.

How has Evonik revised its full-year 2026 adjusted EBITDA outlook, and what was its 2025 result?

Evonik has raised its full-year 2026 adjusted EBITDA forecast to €2.0–€2.2 billion, up from its prior outlook; in 2025, the company reported an adjusted EBITDA of approximately €1.9 billion.

Evonik Reports 24% Year-on-Year Profit Increase

Aug 7, 2026

Evonik reported a 24% year-on-year increase in adjusted EBITDA to €630 million for Q2 2026, raising its full-year outlook to €2–2.2 billion. Growth stemmed from an 11% sales increase and opportunities in advanced technologies and animal nutrition.

ccin

2025-11-04

Evonik beats estimates despite weaker profits

2026-01-23

Argentina urged to adopt long-term industrialization plan to leverage Vaca Muerta shale wealth – Evonik exec

2026-02-05

Evonik Reports Higher Net Profit in Preliminary Results

2026-02-09

Evonik Launches PFAS-Free Liquid Additives

2026-02-10

Evonik to expand HTPB capacity in Germany